Indivior Welcomes Joe Ciaffoni as New Chief Executive Officer

Indivior Welcomes New Leadership

In a significant leadership change, Indivior PLC has announced the appointment of Joe Ciaffoni as the new Chief Executive Officer (CEO) of the company. This decision comes as the current CEO, Mark Crossley, prepares to step down following his notable tenure at the helm of the organization. Ciaffoni, who has been serving as an Independent Non-Executive Director on Indivior's board, will officially take on the role after receiving shareholder approval in the upcoming Annual General Meeting (AGM) in May 2025.

Ciaffoni, aged 53, brings a wealth of experience to this position. With over 30 years in the pharmaceutical and biotech industries, he has held executive roles in several prestigious organizations. Notably, he has served as President and CEO at Collegium Pharmaceutical and has previously held senior positions at Endo International, Biogen, and Shionogi Inc., showcasing a robust background in strategic and operational leadership.

As CEO, Ciaffoni will inherit a company that has made substantial strides in the addiction treatment sector. Under the guidance of Mark Crossley, who has been CEO since June 2020, Indivior has strengthened its commitment to patients suffering from substance use disorders, expanded treatment access, and worked towards pioneering transformative treatments in this critical area. Crossley will continue to support the company's transition process, ensuring stability and continuity as Ciaffoni steps into his new role.

David Wheadon, Chair of Indivior's Board of Directors, expressed his confidence in Ciaffoni, stating, "We are delighted to appoint Joe as our next Chief Executive Officer. He is an accomplished leader with a strong track record of delivering positive outcomes for patients while generating shareholder value." Wheadon highlighted Ciaffoni's mandate to propel Indivior’s growth trajectory, citing the company’s significant untapped potential.

In his statement, Ciaffoni expressed his eagerness to lead Indivior, acknowledging the vital role the company plays in the addiction treatment space. "It is an honor to be appointed as CEO. Indivior is a leader in the addiction treatment space and its work has never been more necessary. I look forward to working with the team to deliver on the Company’s potential and to drive Indivior's future growth for the benefit of all our stakeholders," he remarked.

Mark Crossley, upon his departure, reflected on his decade-long journey with Indivior, emphasizing the organization's shared vision and dedication to patient care. "It has been a tremendous privilege to have worked at Indivior over the last decade, the last five as CEO. I truly believe in our vision and commitment to helping our patients and widening access to treatment," he stated. He also acknowledged the collective efforts of his colleagues in addressing one of the great human crises of our lifetime.

Indivior, headquartered in Richmond, Virginia, is committed to changing lives through innovative medicines for substance use disorders. With a diverse global portfolio focused on evidence-based treatment and a dedication to transforming addiction from a global crisis into a recognized chronic disease, Ciaffoni's leadership will be pivotal in steering the company through its next chapter.

As Indivior embraces this leadership transition, stakeholders are keen to observe how Ciaffoni's extensive expertise will influence the company’s strategic initiatives and commitment to delivering effective treatments for those in need. The upcoming AGM will mark a significant milestone as Indivior prepares for this new era under Ciaffoni's guidance, promising a robust approach to tackling the challenges related to substance use disorders worldwide.